May 2003
Volume 44, Issue 13
ARVO Annual Meeting Abstract  |   May 2003
Loteprednol Etabonate 0.5% (Lotemax) versus Vehicle in the Management of Patients with KCS and at Least Moderate Inflammation
Author Affiliations & Notes
  • S.L. Maskin
    Cornea and Eye Surface Center, Tampa, FL, United States
  • B. Anderson
    Anderson and Associates, Tampa, FL, United States
  • J. Chodosh
    Dean A. McGee Eye Institute, Oklahoma City, OK, United States
  • E.J. Holland
    University of Cincinnati, Cincinnati, OH, United States
  • S.C. Pflugfelder
    Baylor College of Medicine, Houston, TX, United States
  • S.P. Bartels
    Bausch and Lomb, Rochester, NY, United States
  • T. Micuda
    Bausch and Lomb, Rochester, NY, United States
  • R. Vogel
    Rogellen Partners Inc, Sarasota, FL, United States
  • Footnotes
    Commercial Relationships  S.L. Maskin, Bausch and Lomb F, C; B. Anderson, Bausch and Lomb F; J. Chodosh, Bausch and Lomb F; E.J. Holland, Bausch and Lomb F, C; S.C. Pflugfelder, Bausch and Lomb F, C; S.P. Bartels, Bausch and Lomb E; T. Micuda, Bausch and Lomb E; R. Vogel, Bausch and Lomb C.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 686. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S.L. Maskin, B. Anderson, J. Chodosh, E.J. Holland, S.C. Pflugfelder, S.P. Bartels, T. Micuda, R. Vogel; Loteprednol Etabonate 0.5% (Lotemax) versus Vehicle in the Management of Patients with KCS and at Least Moderate Inflammation . Invest. Ophthalmol. Vis. Sci. 2003;44(13):686.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: Some of the signs and symptoms of KCS are believed to be due to inflammatory mediators whose effect is increased by prolonged contact with the cornea and conjunctiva. The use of a steroid (eg: loteprednol etabonate ) may be justified in the management of this condition. Method: After a 2 week run-in on preservative free moisturizing drops, 64 patients with KCS entered a double masked randomized study and received either Lotemax® 0.5% QID (L) or vehicle (V).They were examined after 2 and 4 weeks on study drug, then after 2 weeks without study drug. Symptoms were scored on a visual analog scale (VAS) of 1 -100. Grading for Corneal staining (CS) was 0-4 in 5 areas, Conjunctival hyperemia (CH) as 0-3 in inferior bulbar (IB), nasal bulbar (NB) and inferior tarsal (IT), Lid margin hyperemia (LM) as 0-3. Results: In those patients who had at least moderate inflammation (Total CS >10 or CH >2 in any area, or both of these criteria) there was a significant difference between the treatment groups after 2 weeks on treatment. Table: Inflammatory signs/symptoms: differences between groups (L-V) for change from baseline .While none of the differences between V and L retained statistical significance at 4 weeks the L group was improved relative to the V group, this effect partially regressed when off treatment. Conclusions: The use of topical loteprednol etabonate 0.5% QID may be beneficial in patients who have KCS with at least a moderate inflammatory component.  

* p<0.05

Keywords: cornea: tears/tear film/dry eye • corticosteroids • clinical (human) or epidemiologic studies: tre 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.